Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Akeso, Atom, Eisai, Huadaong, Ideaya, Ipsen, Iregene, JCR Pharmaceuticals, Junshi, Merck, Takeda.
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Cantargia, Nkgen Biotech, Nkmax, Otsuka.
Braveheart Bio Inc. is paying $65 million up front to license Jiangsu Hengrui Pharmaceuticals Co. Ltd.’s oral hypertrophic cardiomyopathy drug candidate called HRS-1893.
Argo Biopharmaceutical Co. Ltd. and its RNAi work drew Novartis AG back to the table for a third time, as the companies entered a potential $5.2 billion deal involving cardiovascular-focused assets, including a right to first negotiation for BW-00112, an angiopoietin-like protein 3-targeting siRNA in phase II testing in severe hypertriglyceridemia.
Epigenic Therapeutics Co. Ltd. closed a $60 million series B round to support clinical development of lead gene therapy candidates EPI-003 for chronic hepatitis B virus and EPI-001 for hypercholesterolemia.
“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at the Global Bio Conference in Seoul, South Korea Sept. 3.
Argenica Therapeutics Ltd. saw its stock drop 56% following mixed results for its ARG-007 phase II Seancon trial in acute ischemic stroke patients undergoing endovascular revascularization, or thrombectomy.
Propanc Biopharma, Inc. plans to acquire $100 million of Ethereum cryptocurrency over the next 12 months to accelerate its pipeline. The company is advancing its lead candidate, PRP, to enter a phase Ib trial in 30 to 40 advanced cancer patients with malignant solid tumors.
RSS
